Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 28;6(12):101197.
doi: 10.1016/j.jhepr.2024.101197. eCollection 2024 Dec.

Reply to: "Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma"

Christiana Graf  1   2 , Christoph Sarrazin  1   3 , Julia Dietz  1
Affiliations

Reply to: "Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma"

Christiana Graf et al. JHEP Rep. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Efficacy of third-line rescue treatment after VOX/VEL/SOF failure. Overall SVR: 93% (n = 14 patients with final treatment outcome). ∗n = 1 patient with post-treatment relapse. G/P, glecaprevir/pibrentasvir; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virologic response; VEL, velpatasvir; VOX, voxilaprevir.
See this image and copyright information in PMC

References

    1. Shah S., Guerra Veloz M.F., Agarwal K., et al. Unlocking hope: Hepatitis C Virus re-treatment strategy for patients with active hepatocellular carcinoma. JHEP Reports. 2024 doi: 10.1016/j.jhepr.2024.101093. - DOI - PMC - PubMed
    1. Fierer D.S., Wyles D.L. Re-Treatment of hepatitis C infection after multiple failures of direct-acting antiviral therapy. Open Forum Infect Dis. 2020;7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148001/ Available at: - PMC - PubMed
    1. Dietz J., Di Maio V.C., de Salazar A., et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2021;74:801–810. - PubMed
    1. Bernhard B., Stickel F. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. Z Gastroenterol. 2020;58:451–455. - PubMed
    1. Wyles D., Weiland O., Yao B., et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70:1019–1023. - PubMed

LinkOut - more resources